Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

IFx-Hu2.0

Other · Immune activation · developed by TuHURA Biosciences

Phase 2/3 Most advanced trial
HURA Developer
1 Registered trials

What is IFx-Hu2.0?

IFx-Hu2.0 (pAc/emm55) is an innate immune agonist given intralesionally. It is being studied in advanced or metastatic Merkel cell carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
pAc/emm55
Drug type
Other
Mechanism
Immune activation
Therapy area
Oncology
Developer
TuHURA Biosciences, Inc. (HURA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06947928 Phase 2/3 Advanced Or Metastatic Merkel Cell Carcinoma Recruiting HURA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Or Metastatic Merkel Cell Carcinoma

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the HURA page.

Follow HURA, the company behind IFx-Hu2.0

See HURA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

HURA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.